Mostrar el registro sencillo del ítem
dc.contributor.author | Pérez-Yanes, Silvia | |
dc.contributor.author | Pernas, Maria | |
dc.contributor.author | Marfil, Silvia | |
dc.contributor.author | Cabrera-Rodríguez, Romina | |
dc.contributor.author | Ortiz, Raquel | |
dc.contributor.author | Urrea, Víctor | |
dc.contributor.author | Rovirosa, Carla | |
dc.contributor.author | Estévez-Herrera, Judith | |
dc.contributor.author | Olivares, Isabel | |
dc.contributor.author | Casado, Concepcion | |
dc.contributor.author | Lopez-Galindez, Luis Cecilio | |
dc.contributor.author | Blanco, Julià | |
dc.contributor.author | Valenzuela-Fernández, Agustín | |
dc.date.accessioned | 2022-08-05T08:23:00Z | |
dc.date.available | 2022-08-05T08:23:00Z | |
dc.date.issued | 2022-03-24 | |
dc.identifier.citation | Front Microbiol. 2022 Mar 24;13:763039. | es_ES |
dc.identifier.issn | 1664-302X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14858 | |
dc.description.abstract | The understanding of HIV-1 pathogenesis and clinical progression is incomplete due to the variable contribution of host, immune, and viral factors. The involvement of viral factors has been investigated in extreme clinical phenotypes from rapid progressors to long-term non-progressors (LTNPs). Among HIV-1 proteins, the envelope glycoprotein complex (Env) has been concentrated on in many studies for its important role in the immune response and in the first steps of viral replication. In this study, we analyzed the contribution of 41 Envs from 24 patients with different clinical progression rates and viral loads (VLs), LTNP-Elite Controllers (LTNP-ECs); Viremic LTNPs (vLTNPs), and non-controller individuals contemporary to LTNPs or recent, named Old and Modern progressors. We studied the Env expression, the fusion and cell-to-cell transfer capacities, as well as viral infectivity. The sequence and phylogenetic analysis of Envs were also performed. In every functional characteristic, the Envs from subjects with viral control (LTNP-ECs and vLTNPs) showed significant lower performance compared to those from the progressor individuals (Old and Modern). Regarding sequence analysis, the variable loops of the gp120 subunit of the Env (i.e., V2, V4, and mainly V5) of the progressor individuals showed longer and more glycosylated sequences than controller subjects. Therefore, HIV-1 Envs from virus of patients presenting viremic control and the non-progressor clinical phenotype showed poor viral functions and shorter sequences, whereas functional Envs were associated with virus of patients lacking virological control and with progressor clinical phenotypes. These correlations support the role of Env genotypic and phenotypic characteristics in the in vivo HIV-1 infection and pathogenesis. | es_ES |
dc.description.sponsorship | This work is supported by Spanish AIDS network “Red Temática Cooperativa de Investigación en SIDA” RD12/0017/0002, RD12/0017/0028, RD12/0017/0034, RD16/0025/0011, RDCIII16/0002/0005, and RD16/0025/0041 as part of the Plan Nacional R + D + I and cofunded by Spanish “Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).” JB is a researcher from “Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol” supported by the Health Department of the Catalan Government/Generalitat de Catalunya and ISCIII grant numbers PI17/01318 and PI20/00093 (to JB). Work in CL-G and CC lab was supported by grants SAF (2010-17226) and (2016-77894-R) from MINECO (Spain) and FIS (PI 13/02269 and PI20/00093, ISCIII). AV-F’s Lab is supported by the European Regional Development Fund (ERDF), RTI2018-093747-B-100 (“Ministerio de Ciencia e Innovación,” Spain), “Ministerio de Ciencia, Innovación y Universidades” (Spain), ProID2020010093 (“Agencia Canaria de Investigación, Innovación y Sociedad de la Información” and European Social Fund), UNLL10-3E-783 (ERDF and “Fundación CajaCanarias”) and “SEGAI-ULL.” SP-Y is funded by “Fundación Doctor Manuel Morales” (La Palma, Spain) and “Contrato Predoctoral Ministerio-ULL Formación de Doctores” (2019 Program; “Ministerio de Ciencia, Innovación y Universidades,” Spain). RC-R is funded by RD16/0025/0011 and ProID2020010093 (“Agencia Canaria de Investigación, Innovación y Sociedad de la Información” and European Social Fund). JE-H is funded by the Cabildo Tenerife “Agustin de Betancourt” 2017 Program. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | HIV | es_ES |
dc.subject | Elite controllers (HIV-1 EC) | es_ES |
dc.subject | Functional defect | es_ES |
dc.subject | Functional envelope | es_ES |
dc.subject | Lack of virological control | es_ES |
dc.subject | Viral envelope | es_ES |
dc.title | The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 35401460 | es_ES |
dc.format.volume | 13 | es_ES |
dc.format.page | 763039 | es_ES |
dc.identifier.doi | 10.3389/fmicb.2022.763039 | es_ES |
dc.contributor.funder | Red de Investigación Cooperativa en Investigación en Sida (España) | es_ES |
dc.contributor.funder | Plan de Recuperación, Transformación y Resiliencia (España) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | es_ES |
dc.contributor.funder | Agencia Canaria de Investigación, Innovación y Sociedad de la Información | es_ES |
dc.contributor.funder | Unión Europea. Fondo Social Europeo (ESF/FSE) | es_ES |
dc.contributor.funder | Fundación CajaCanarias | es_ES |
dc.contributor.funder | Fundación Doctor Manuel Morales | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fmicb.2022.763039 | es_ES |
dc.identifier.journal | Frontiers in Microbiology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0002/ES/SIDA/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD12/0017/0028 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD12/0017/0034 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0011/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0041/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RTI2018-093747-B-100 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/ProID2020010093 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SAF2016-77894-R | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SAF/2010-17226 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/RD12/0017/0028 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/RDCIII16/0002/0005 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI17/01318 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI13/02269 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI20/00093 | es_ES |